<DOC>
	<DOC>NCT02897817</DOC>
	<brief_summary>The aim of this study is to evaluate, at 6 months, the rate of patients whose adherence to injectable MTX remained strong or improved according to patient-reported outcome.</brief_summary>
	<brief_title>Treatment Adherence to Injectable Methotrexate in Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Adult patients (≥ 18 years old) Patients with a diagnosis of RA as confirmed by the ACR/EULAR (2010) Classification Criteria for Rheumatoid Arthritis Patients: currently treated with oral MTX and requiring a switch to an injectable MTX* or currently treated with an injectable MTX* and eligible for a change of MTX injection device* Patients informed about and accepting the computer processing of their medical data and their right of accesss and correction. Patients who refuse to participate in the study or are unable to fill out the patient diary. *On the basis of the products marketed at the time of submission of the study to Oversight Authorities (Méthotrexate Biodim®, Metoject® and imeth®).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Methotrexate</keyword>
	<keyword>Treatment adherence</keyword>
</DOC>